Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment

Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased th...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuccio, Fabio Giuseppe, Lo Re, Marianna, Bertolotto, Antonio, Capobianco, Marco, Solaro, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576324/
https://www.ncbi.nlm.nih.gov/pubmed/33296987
http://dx.doi.org/10.1016/j.msard.2020.102592
_version_ 1783597996908216320
author Masuccio, Fabio Giuseppe
Lo Re, Marianna
Bertolotto, Antonio
Capobianco, Marco
Solaro, Claudio
author_facet Masuccio, Fabio Giuseppe
Lo Re, Marianna
Bertolotto, Antonio
Capobianco, Marco
Solaro, Claudio
author_sort Masuccio, Fabio Giuseppe
collection PubMed
description Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased the survival rate. We present the case of a 31-years-old Caucasian patient who experienced an almost asymptomatic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection during treatment with tocilizumab, which was continued due to the very high risk of relapses of the patient. According to this case, tocilizumab might be not discontinued during COVID-19.
format Online
Article
Text
id pubmed-7576324
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-75763242020-10-21 Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment Masuccio, Fabio Giuseppe Lo Re, Marianna Bertolotto, Antonio Capobianco, Marco Solaro, Claudio Mult Scler Relat Disord Correspondence Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased the survival rate. We present the case of a 31-years-old Caucasian patient who experienced an almost asymptomatic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection during treatment with tocilizumab, which was continued due to the very high risk of relapses of the patient. According to this case, tocilizumab might be not discontinued during COVID-19. Elsevier B.V. 2020-11 2020-10-21 /pmc/articles/PMC7576324/ /pubmed/33296987 http://dx.doi.org/10.1016/j.msard.2020.102592 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Masuccio, Fabio Giuseppe
Lo Re, Marianna
Bertolotto, Antonio
Capobianco, Marco
Solaro, Claudio
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
title Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
title_full Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
title_fullStr Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
title_full_unstemmed Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
title_short Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
title_sort benign sars-cov-2 infection in mog-antibodies associated disorder during tocilizumab treatment
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576324/
https://www.ncbi.nlm.nih.gov/pubmed/33296987
http://dx.doi.org/10.1016/j.msard.2020.102592
work_keys_str_mv AT masucciofabiogiuseppe benignsarscov2infectioninmogantibodiesassociateddisorderduringtocilizumabtreatment
AT loremarianna benignsarscov2infectioninmogantibodiesassociateddisorderduringtocilizumabtreatment
AT bertolottoantonio benignsarscov2infectioninmogantibodiesassociateddisorderduringtocilizumabtreatment
AT capobiancomarco benignsarscov2infectioninmogantibodiesassociateddisorderduringtocilizumabtreatment
AT solaroclaudio benignsarscov2infectioninmogantibodiesassociateddisorderduringtocilizumabtreatment

Ejemplares similares